Blade Therapeutics   Report issue

For profit Phase 1 Phase 2
Founded: South San Francisco CA United States (2015)

Organization Overview

First Clinical Trial
2018
NCT03559166
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Blade Therapeutics

Active Ingredients

Drugs in Phase 2 Trials (2)

bld-2660 (4 trials)

Cudetaxestat (5 trials)

Drugs in Phase 1 Trials (2)

nintedanib (ofev) (1 trial)

pirfenidone (esbriet) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fatty Liver (Phase 1)

Fibrosis (Phase 2)

Idiopathic Pulmonary Fibrosis (Phase 2)

Liver Cirrhosis (Phase 1)

Liver Diseases (Phase 1)

Non-alcoholic Fatty Liver Disease (Phase 1)

Pulmonary Fibrosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 4